FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Horstmann

Research Profile

Disorders

Procedures

Concepts & Ideas

Living Beings

Infants

Physiology

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Helena Brauer; Martin Horstmann; Carsten Müller-Tidow; Julia Strauss; Wiebke Wegner; Manfred Jücker
Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Linda Zuurbier; Jessica G C A M Buijs-Gladdines; Valerie Calvert; Martin Horstmann; Willem A Kamps; Clarissa Kooi; Emanuel F Petricoin; Rob Pieters; Willem K Smits; Edwin Sonneveld; Anjo J P Veerman; Maartje J Vuerhard; Jules P P Meijerink
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Gabriele Escherich; Ulrich Göbel; Ulrike B Graubner; Martin Horstmann; Gritta Janka; Norbert Jorch; G J L Kaspers; Karin Kazemier; Arnulf Pekrun; Rob Pieters; Anja Tröger; Martin Zimmermann; Udo zur Stadt; Monique L den Boer
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Horstmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Helena Brauer; Martin Horstmann; Carsten Müller-Tidow; Julia Strauss; Wiebke Wegner; Manfred Jücker
Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Cellular signalling 2012;24(11):2095-101.
2012: Linda Zuurbier; Jessica G C A M Buijs-Gladdines; Valerie Calvert; Martin Horstmann; Willem A Kamps; Clarissa Kooi; Emanuel F Petricoin; Rob Pieters; Willem K Smits; Edwin Sonneveld; Anjo J P Veerman; Maartje J Vuerhard; Jules P P Meijerink
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Haematologica 2012;97(9):1405-13.
2011: Gabriele Escherich; Ulrich Göbel; Ulrike B Graubner; Martin Horstmann; Gritta Janka; Norbert Jorch; G J L Kaspers; Karin Kazemier; Arnulf Pekrun; Rob Pieters; Anja Tröger; Martin Zimmermann; Udo zur Stadt; Monique L den Boer
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Haematologica 2011;96(6):854-62.
2011: Irene Homminga; Rob Pieters; Anton W Langerak; Johan J de Rooi; Andrew Stubbs; Monique Verstegen; Maartje Vuerhard; Jessica Buijs-Gladdines; Clarissa Kooi; Petra Klous; Pieter Van Vlierberghe; Adolfo Ferrando; Jean Michel Cayuela; Brenda Verhaaf; Berna Beverloo; Martin Horstmann; Valerie de Haas; Anna-Sophia Wiekmeijer; Karin Pike-Overzet; Frank Staal; Wouter de Laat; Jean Soulier; Francois Sigaux; Jules P P Meijerink
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.
Cancer cell 2011;19(4):484-97.
2010: L Zuurbier; I Homminga; V Calvert; M L te Winkel; J G C A M Buijs-Gladdines; C Kooi; W K Smits; E Sonneveld; A J P Veerman; Willem A Kamps; Martin Horstmann; E F Petricoin; Rob Pieters; Jules P P Meijerink
NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
Leukemia 2010;24(12):2014-22.
2010: Gabriele Escherich; Martin Horstmann; M Zimmermann; Gritta E Janka-Schaub
Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Leukemia 2010;24(2):298-308.
2008: Pieter Van Vlierberghe; Martine van Grotel; Joëlle Tchinda; Charles Lee; Berna Beverloo; Peter van der Spek; Andrew Stubbs; Jan Cools; Kyosuke Nagata; Maarten Fornerod; Jessica Buijs-Gladdines; Martin Horstmann; Elisabeth R van Wering; Jean Soulier; Rob Pieters; Jules P P Meijerink
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.
Blood 2008;111(9):4668-80.
2008: Brian Balgobind; Pieter Van Vlierberghe; Ans M W van den Ouweland; Berna Beverloo; Joan N R Terlouw-Kromosoeto; Elisabeth R van Wering; Dirk Reinhardt; Martin Horstmann; G J L Kaspers; Rob Pieters; Christian M Zwaan; Marry M van den Heuvel-Eibrink; Jules P P Meijerink
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.
Blood 2008;111(8):4322-8.
2008: Pieter Van Vlierberghe; I Homminga; L Zuurbier; J Gladdines-Buijs; Elisabeth R van Wering; Martin Horstmann; Berna Beverloo; Rob Pieters; Jules P P Meijerink
Cooperative genetic defects in TLX3 rearranged pediatric T-ALL.
Leukemia 2008;22(4):762-70.
2007: A Metzner; Martin Horstmann; Boris Fehse; G Ortmeyer; C M Niemeyer; Carol Stocking; Georg W Mayr; Manfred Jücker
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Gene therapy 2007;14(8):699-703.
2006: Martine van Grotel; Jules P P Meijerink; Berna Beverloo; Anton Langerak; Jessica G C A M Buys-Gladdines; Pauline Schneider; Tim S Poulsen; Monique L den Boer; Martin Horstmann; Willem A Kamps; Anjo J P Veerman; Elisabeth R van Wering; Max M van Noesel; Rob Pieters
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
Haematologica 2006;91(9):1212-21.
2006: Kevin Dierck; Kazuya Machida; Anja Voigt; Julian Thimm; Martin Horstmann; Walter Fiedler; Bruce J Mayer; Peter Nollau
Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains.
Nature methods 2006;3(9):737-44.
2005: Martin Horstmann; Wolf Hassenpflug; Udo zur Stadt; Gabi Escherich; Gritta Janka; Hartmut Kabisch
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Haematologica 2005;90(12):1701-3.
2005: Ronald W Stam; Monique L den Boer; Pauline Schneider; Peter Nollau; Martin Horstmann; Berna Beverloo; Ella van der Voort; Maria Grazia Valsecchi; Paola de Lorenzo; Stephen E Sallan; Scott A Armstrong; Rob Pieters
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Blood 2005;106(7):2484-90.
2003: Martin Horstmann; Eva Neumaier-Probst; Zoltan Lukacs; Robert Steinfeld; Kurt Ullrich; Alfried Kohlschuetter
Infantile cobalamin deficiency with cerebral lactate accumulation and sustained choline depletion.
Neuropediatrics 2003;34(5):261-4.
2002: Nicolaus Kröger; Tatjana Zabelina; Helmut Renges; William H Krüger; Uwe Kordes; Johannes Rischewski; J Schrum; Martin Horstmann; Francis Ayuk; Rudolf Erttmann; Hartmut Kabisch; Axel R Zander
Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Annals of hematology 2002;81(11):627-31.
1999: Matthias Dürken; Martin Horstmann; P Bieling; Rudolf Erttmann; Hartmut Kabisch; C Löliger; E Marion Schneider; Hans-Henning Hellwege; William H Krüger; Nicolaus Kröger; Axel R Zander; Gritta Janka
Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients.
British journal of haematology 1999;106(4):1052-8.
1997: Axel R Zander; C Berger; Nicolaus Kröger; M Stockshläder; William H Krüger; Martin Horstmann; Jan Grimm; W Zeller; Hartmut Kabisch; Rudolf Erttmann; P Schönrock; Rolf Kuse; Dietrich Braumann; Hans-Jochen Illiger; Walter Fiedler; M de Witt; K D Hossfeld; HJ Weh
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2671-5.
1997: B Anderegg; Martin Horstmann; M Ernst; Hartmut Kabisch
Transcription of tal-1, a putative oncogene playing an important role in childhood T-ALL, can be shown in normal peripheral blood cells by a highly sensitive RT-PCR assay.
Pediatric hematology and oncology 1997;14(4):349-58.
1997: B Anderegg; Martin Horstmann; Hartmut Kabisch
Effects of anti-tal-1 oligodeoxynucleotides in T-ALL cell lines.
Cancer gene therapy 1997;4(2):84-90.
1997: Martin Horstmann; M Pösl; R B Scholz; B Anderegg; P Simon; K Baumgaertl; G Delling; H Kabisch
Frequent reduction or loss of DCC gene expression in human osteosarcoma.
British journal of cancer 1997;75(9):1309-17.
1996: Martin Horstmann; A Argyriou-Tirita; Arndt Borkhardt; Hartmut Kabisch; P Kapaun; K Winkler; O A Haas
MLL/ENL fusion in congenital acute lymphoblastic leukemia with a unique t(11;18;19).
Cancer genetics and cytogenetics 1996;88(2):103-9.
1996: Marcus Stockschläder; W Krüger; A tom Dieck; Martin Horstmann; M Altnöder; C Löliger; W Fiedler; MM Hoffknecht; Rudolf Erttmann; Axel Zander
Use of cryopreserved bone marrow in unrelated allogeneic transplantation.
Bone marrow transplantation 1996;17(2):197-9.
1996: W Krüger; I Sobottka; Marcus Stockschläder; K Mross; MM Hoffknecht; Bettina Rüssmann; Martin Horstmann; R Betker; A Zander
Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the Mic values.
Scandinavian journal of infectious diseases 1996;28(3):313-6.
1996: Martin Horstmann; G Kroschke; Marcus Stockschläder; R Betker; W Krüger; Rudolf Erttmann; Hartmut Kabisch; Axel Zander
Early toxicity of intensified conditioning with etoposide combined with total body irradiation/cyclophosphamide or busulfan/cyclophosphamide in children undergoing autologous or allogeneic bone marrow transplantation.
Pediatric hematology and oncology 1996;13(1):45-53.
1995: W Krüger; Marcus Stockschläder; Bettina Rüssmann; C Berger; MM Hoffknecht; I Sobottka; B Kohlschütter; G Kroschke; Nicolaus Kröger; Martin Horstmann
Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
British journal of haematology 1995;91(3):684-90.
1995: Martin Horstmann; Marcus Stockschläder; W Krüger; MM Hoffknecht; R Betker; Hartmut Kabisch; Axel Zander
Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results.
Annals of hematology 1995;71(2):77-81.
1995: Martin Horstmann; Marcus Stockschläder; Hartmut Kabisch; Axel Zander
Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors.
Blood 1995;85(5):1404-5.
1994: Martin Horstmann; Rudolf Erttmann; K Winkler
Relapse of MALT lymphoma associated with Helicobacter pylori after antibiotic treatment.
Lancet 1994;343(8905):1098-9.